What is a stock summary page? Click here for an overview.
Business Description
Zai Lab Ltd
ISIN : KYG9887T1168
Share Class Description:
STU:1ZLB: Ordinary SharesCompare
Compare
Traded in other countries / regions
ZLAB.USA09688.Hong Kong1ZLB.GermanyZLAB N.Mexico IPO Date
2020-10-21Description
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.08 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.63 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.25 | |||||
| Beneish M-Score | -1.86 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 37.5 | |||||
| 3-Year EBITDA Growth Rate | 30.8 | |||||
| 3-Year EPS without NRI Growth Rate | 31.6 | |||||
| 3-Year FCF Growth Rate | 23 | |||||
| 3-Year Book Growth Rate | -18.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 44.96 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.21 | |||||
| 9-Day RSI | 48.14 | |||||
| 14-Day RSI | 53.28 | |||||
| 3-1 Month Momentum % | 20.15 | |||||
| 6-1 Month Momentum % | 69.47 | |||||
| 12-1 Month Momentum % | 114.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.51 | |||||
| Quick Ratio | 3.38 | |||||
| Cash Ratio | 2.6 | |||||
| Days Inventory | 100.69 | |||||
| Days Sales Outstanding | 59.35 | |||||
| Days Payable | 271.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.1 | |||||
| Shareholder Yield % | -7.87 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.94 | |||||
| Operating Margin % | -69.36 | |||||
| Net Margin % | -64.44 | |||||
| FCF Margin % | -69.26 | |||||
| ROE % | -34.09 | |||||
| ROA % | -24.8 | |||||
| ROIC % | -132.95 | |||||
| 3-Year ROIIC % | 260.56 | |||||
| ROC (Joel Greenblatt) % | -198.25 | |||||
| ROCE % | -32.25 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.21 | |||||
| PB Ratio | 4.24 | |||||
| Price-to-Tangible-Book | 4.87 | |||||
| EV-to-EBIT | -12.77 | |||||
| EV-to-Forward-EBIT | -6.15 | |||||
| EV-to-EBITDA | -13.4 | |||||
| EV-to-Forward-EBITDA | -6.15 | |||||
| EV-to-Revenue | 8.16 | |||||
| EV-to-Forward-Revenue | 3.25 | |||||
| EV-to-FCF | -12.68 | |||||
| Price-to-GF-Value | 0.75 | |||||
| Price-to-Net-Current-Asset-Value | 5.34 | |||||
| Price-to-Net-Cash | 8.81 | |||||
| Earnings Yield (Greenblatt) % | -7.83 | |||||
| FCF Yield % | -7.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zai Lab Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 369.848 | ||
| EPS (TTM) (€) | -0.232 | ||
| Beta | 1.24 | ||
| 3-Year Sharpe Ratio | -0.25 | ||
| 3-Year Sortino Ratio | -0.32 | ||
| Volatility % | 54.06 | ||
| 14-Day RSI | 53.28 | ||
| 14-Day ATR (€) | 0.102055 | ||
| 20-Day SMA (€) | 3.295 | ||
| 12-1 Month Momentum % | 114.67 | ||
| 52-Week Range (€) | 1.24 - 3.56 | ||
| Shares Outstanding (Mil) | 1,082.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zai Lab Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zai Lab Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zai Lab Ltd Frequently Asked Questions
What is Zai Lab Ltd(STU:1ZLB)'s stock price today?
The current price of STU:1ZLB is €3.26. The 52 week high of STU:1ZLB is €3.56 and 52 week low is €1.24.
When is next earnings date of Zai Lab Ltd(STU:1ZLB)?
The next earnings date of Zai Lab Ltd(STU:1ZLB) is 2025-05-08 Est..
Does Zai Lab Ltd(STU:1ZLB) pay dividends? If so, how much?
Zai Lab Ltd(STU:1ZLB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers